Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors
Thomas N. Burn, Jan Schröder, Luke C. Gandolfo, Maleika Osman, Elanor N. Wainwright, Enid Y.N. Lam, Keely M. McDonald, Rachel Evans, Shihan Li, Daniel Rawlinson, Lachlan Dryburgh, Ali Zaid, Zoltan Maliga, Dominick Schienstock, Philippa Meiser, Hyun Jae Lee, Hongjin Lai, Marcela L. Moreira, Pirooz Zareie, Louis H-Y. Lee, Lutfi Huq, Susan N. Christo, Justine J. W. Seow, Keith A. Ching, Stéphane M. Guillaume, Kathy Knezevic, Simone L. Park, Maximilien Evrard, Jason Waithman, Thomas Gebhardt, Scott N. Mueller, Georgina Riddiough, Marcos V. Perini, Simon C. H. Tsao, Terence P. Speed, Peter K. Sorger, Sherene Loi, Francis R. Carbone, Stéphanie Gras, Timothy S. Fisher, Bas Baaten, Mark A. Dawson, Laura K. Mackay
Abstract
Abstract CD8 + T cells are an important weapon in the therapeutic armamentarium against cancer. While CD8 + CD103 + T cells with a tissue-resident memory T (T RM ) cell phenotype are associated with favorable prognoses, the tumor microenvironment also contains dysfunctional exhausted T (T EX ) cells that exhibit a variety of T RM -like features. Here we deconvolute T RM and T EX cells across human cancers, ascribing markers and gene signatures that distinguish these populations and enable their functional distinction. Although T RM cells have superior functionality and are associated with long-term survival post-tumor resection, they are not associated with responsiveness to immune checkpoint blockade. Tumor-associated T EX and T RM cells are clonally distinct, with the latter comprising tumor-independent bystanders and tumor-specific cells segregated from cognate antigen. Intratumoral T RM cells can be forced toward an exhausted fate when chronic antigen stimulation occurs, indicating that the presence or absence of continuous antigen exposure within the microenvironment is the key distinction between tumor-associated T EX and T RM populations. These results highlight unique functions for T RM and T EX cells in tumor control, underscoring the need for distinct strategies to harness these populations for cancer therapies.